During the 8th annual Microbiome Movement Drug Development Europe, held in Barcelona (Spain), Microbiomepost conducted an exclusive interview with Antonio Gomes, Principal Scientist at Xbiome, a leading company in microbiome immuno-oncology.
We discussed the emerging role of the integration of AI in microbiome small molecule discovery and therapeutics.
This approach is revolutionizing the field by employing deep learning techniques to refine the prediction of natural product structures directly from gene sets. Not only enhances the accuracy of predictions but also facilitates the high-throughput categorization of these natural products through the application of chemoinformatics.
Furthermore, this innovative use of AI is paving the way for the exploration of new therapeutic natural products derived from patient microbiomes, offering promising avenues for personalized medicine and novel treatment strategies.
